NCT00546793 - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

NHLLymphoma, Non-HodgkinLymphoma, B-CellLymphoma, FollicularLymphoma, Intermediate-GradeLymphoma, Large-CellLymphoma, Low-GradeLymphoma, Mixed-CellLymphoma, Small-CellLeukemia, Lymphocytic, ChronicLeukemia, B-Cell, ChronicLeukemia, ProlymphocyticLeukemia, Small LymphocyticLymphoma, Small LymphocyticLymphoma, Lymphoplasmacytoid, CLLLymphoplasmacytoid Lymphoma, CLLCLLSLL

Interventions

BIOLOGICAL

veltuzumab

veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.

Trial Locations (5)

10021

New York Hospital Weill Cornell Medical Center, New York

31405

Lewis Cancer Center and Research Pavilion, Savannah

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

07834

Cancer Care at Saint Clare's/Saint Clares Hospital Oncology & Hematology Specialists, P.A., Denville

07950

Morristown Memorial Hospital, Morristown